Clinical trials: Insulin Response
Hepatitis C, Chronic, Hepatitis C Virus
Effect of Insulin Resistance on the Safety and Efficacy of Pegylated Interferon and Ribavirin Treatment in HCV (Study P05562)
Naïve patients with chronic hepatitis C (CHC) of any genotype will be treated with a standard treatment regimen (pegylated interferon and ribavirin) according to routine clinical practice in Russia.
- Trial name
- NCT00705224
- Testing
- Pegylated Interferon, Ribavirin
- Volunteers
- 250 people
- Sponsor
- Merck Sharp & Dohme LLC
Nutritional and Metabolic Diseases, Inflammation
A Study of Strawberries and Disease Risk
The purpose of this study is to test whether compounds found in strawberries (polyphenolics which are typically found in berry products, tea, coffee, red wine, and chocolate) will help reduce insulin resistance and inflammation…
- Conditions
- Nutritional and Metabolic Diseases, Inflammation, Physiological Responses
- Trial name
- STRB (NCT01199848)
- Testing
- 10G, 20G, 40G
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Clinical Nutrition Research Center, Illinois Institute of Technology
Hepatitis C, Chronic, Insulin Resistance
Study of Response in Chronic Hepatitis C (CHC) Participants Genotype 1 With Insulin Resistance and Prolonged Treatment Duration in Late Responders (P04823/MK-4031-303)
This is a Phase 3b/4, prospective, open-label, randomized, multicenter study of peginterferon alfa-2b plus ribavirin in participants with chronic hepatitis C, genotype 1.
- Trial name
- NCT00493805
- Testing
- Combination of pegylated interferon alfa-2b and ribavirin
- Volunteers
- 59 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 1 Diabetes Mellitus
Assess the Efficacy of the Low Glucose Suspend (LGS) Feature in the MiniMed Paradigm® X54 System
The purpose of this study is to assess the efficacy of the Low Glucose Suspend (LGS) feature in reducing hypoglycemia with the MiniMed Paradigm® X54 System with hypoglycemic induction from exercise.
- Trial name
- NCT01148862
- Testing
- The MiniMed Paradigm® X54 System
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 1 Diabetes
Outpatient Study to Evaluate Safety and Effectiveness of the Low Glucose Suspend Feature
Introduction: The purpose of the pivotal In Home study is to collect clinical data on the safety and efficacy of the Paradigm LGS System in the actual use environment and by the intended use population.
- Trial name
- ASPIRE (NCT01497938)
- Testing
- Medtronic MMT-754 Veo Insulin pump testing Low Glucose Suspend (LGS) feature, Medtronic (NO LGS FEATURE ) using Paradigm® Revel™2.0 Pump
- Where
- 17 sites in United States
- Volunteers
- 247 people
- Sponsor
- Medtronic MiniMed, Inc.
Pharmacodynamic Response to Small Doses of Insulin
Transdermal Insulin Response In Healthy Volunteers
Bio-fermentation produced Human insulin is available without prescription in the U.S. This study is a physician-initiated trial of a formula enabling transdermal delivery of human insulin.
- Trial name
- NCT04857320
- Testing
- Human insulin
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Transdermal Delivery Solutions Corp
Diabetes Mellitus, Type 1
A Study to Compare and Measure the Effects of Insulin Peglispro (LY2605541) and Glargine on Meal Time Insulin Requirements
This study will look into how a base dose of insulin peglispro and insulin glargine will affect the meal time dose and efficacy of insulin lispro in type 1 diabetics.
- Trial name
- NCT02152384
- Testing
- Insulin Peglispro, Insulin Lispro, Insulin Glargine
- Where
- Germany
- Volunteers
- 28 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Effect of LY2189265 on Insulin Secretion in Response to Intravenous Glucose
The purpose of this study is to measure the effect of LY2189265 to increase insulin levels in response to glucose intake.
- Trial name
- NCT01300260
- Testing
- LY2189265, Insulin, Glucose
- Where
- Germany
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Liquid Meal Study With Insulin Lispro With/Without Recombinant Human Hyaluronidase PH20 (rHuPH20) and Regular Human Insulin With rHuPH20 to Compare Pharmacokinetics, Postprandial Glycemic Response, and Optimal Insulin Dose in Participants With Type 2 Diabetes Mellitus (T2DM)
This is a single-center, Phase 2, randomized, double-blind, 3-way crossover meal study in participants with Type 2 Diabetes Mellitus (T2DM) to determine the optimum dose and compare the pharmacokinetics (PK) and postprandial…
- Trial name
- NCT00916357
- Testing
- Humalog, Humulin-R, Recombinant human hyaluronidase PH20 (rHuPH20)
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Halozyme Therapeutics
Insulin Resistance, Diabetes
Acute Effect of HP-211 (Axulin) on Blood Glucose and Serum Insulin Responses in Healthy Lean and Overweight Humans
Blood sugar levels are controlled by insulin, a hormone made by cells in the pancreas. After a meal, carbohydrates are broken down into glucose (blood sugar) which is absorbed from the intestine into the blood leading to a rise…
- Trial name
- NCT03135015
- Testing
- 2g capsules, 4g capsules, Water Control
- Where
- Canada
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Housey Healthcare ULC
Type 1 Diabetes Mellitus
A Study of How Insulin Peglispro (LY2605541) and Insulin Glargine Affect the Breakdown of Fat and Sugar in Type 1 Diabetics
This is a two-period study of participants with type 1 diabetes mellitus (T1DM). In each period, participants will receive once daily injections of stable dose LY2605541 or insulin glargine for 28 to 35 days followed by…
- Trial name
- NCT01925989
- Testing
- LY2605541, Insulin Glargine
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes Mellitus
Phase II Pharmacokinetics Study of Humalog and Humulin-R With and Without rHuPH20 in Type 1 Diabetes Mellitus
Humalog and Humulin-R (recombinant human insulin) are Food and Drug Administration (FDA) approved medications for the treatment of diabetes mellitus.
- Trial name
- NCT00774800
- Testing
- Humalog, Humulin-R, Recombinant human hyaluronidase PH20 (rHuPH20)
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Halozyme Therapeutics
Hypoglycemia Unawareness, Diabetes Mellitus, Type 1
Glucagon Infusion in T1D Patients With Recurrent Severe Hypoglycemia: Effects on Counter-Regulatory Responses
This is a prospective, randomized, controlled, double-blind, parallel 4-group trial with the primary analysis after 4 weeks of treatment with continuous subcutaneous glucagon infusion (CSGI) or placebo.
- Trial name
- NCT03490942
- Testing
- Glucagon
- Where
- 5 sites in United States
- Volunteers
- 49 people
- Sponsor
- Xeris Pharmaceuticals
Diabetes Mellitus, Type 1
A Study of LY2605541 and Glargine in Participants With Type 1 Diabetes
This study has 2 parts. Each participant will receive a daily injection of LY2605541 during one treatment period and a daily injection of insulin glargine during one treatment period.
- Trial name
- NCT01769404
- Testing
- LY2605541, Insulin Glargine
- Where
- Germany
- Volunteers
- 25 people
- Sponsor
- Eli Lilly and Company